This website (the "Site") contains information about Otsuka America Pharmaceutical, Inc. ("OAPI") and Otsuka Pharmaceutical Development & Commercialization, Inc. ("OPDC”), (collectively, "Otsuka," the "Company," "we", "our" or "us"). Access to and use of this Site is subject to the following terms and conditions and all applicable laws. By accessing and using the Site, you agree to be bound by and to comply with this Terms of Use Agreement without limitation or qualification and you acknowledge that it supersedes any other agreement between you and Company regarding this subject matter. If you do not agree with these Terms of Use, please exit and do not use the Site. These terms of use may be revised by Company from time to time and you should therefore review them on your next visit to the Site. Your continued use of the Site following any such posting will be deemed as consent to the new notice, term or condition. 

1. THE SITE AND THE INFORMATION ARE PROVIDED “AS IS.” COMPANY MAKES NO REPRESENTATION OR WARRANTY OF ANY KIND (INCLUDING REPRESENTATIONS OR WARRANTIES AS TO THE ACCURACY OR COMPLETENESS OF ANY INFORMATION CONTAINED OR REFERENCED ON THE SITE), EITHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT. COMPANY EXPRESSLY DISCLAIMS ANY OBLIGATION TO UPDATE SAID INFORMATION. COMPANY FURTHER ASSUMES NO LIABILITY OR RESPONSIBILITY FOR ANY ERRORS OR OMISSIONS IN THE CONTENT OF THE SITE. 

2. ALL USERS OF THE SITE AGREE THAT ACCESS TO AND THE CONTENTS THEREOF ARE AT THEIR OWN RISK. COMPANY DOES NOT WARRANT THAT THIS SITE OR ITS SERVERS ARE FREE FROM VIRUSES OR OTHER HARMFUL COMPONENTS. IN NO EVENT WILL COMPANY BE LIABLE TO ANY PARTY FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL, OR PUNITIVE DAMAGES RESULTING FROM ANY USE OF, ACCESS OF OR INABILITY TO USE THIS WEBSITE, THE INFORMATION CONTAINED HEREIN, OR ANY OTHER HYPERLINKED OR REFERENCED WEBSITE, INCLUDING, WITHOUT LIMITATION, ANY LOST PROFITS, BUSINESS INTERRUPTION, LOSS OF PROGRAMS OR OTHER DATA ON YOUR INFORMATION HANDLING SYSTEM OR OTHERWISE, EVEN IF WE ARE EXPRESSLY ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 

3. Subject to applicable terms and conditions of Company’s Privacy Policy, any communication from you to Company via the Site shall be deemed to be non-confidential and non-proprietary and Company shall have no obligation of any kind with respect to such information and shall be free to reproduce, use, disclose, and distribute the information to others without limitation and without compensation to you. Company shall be free to use any ideas, concepts, know-how, or techniques contained in such communication for any purpose without compensation to you, including without limitation for developing, manufacturing and marketing products incorporating such information. 

4. The Information may contain technical inaccuracies or typographical errors. Company reserves the right to make changes, corrections, and/or improvements to the Information, and to the products and programs described in such Information, at any time without notice. 

5. Certain sections of the Site contain information about Company's products that are not available in all countries. Approved indications, dosages, restrictions and product presentations may vary from country to country where such products are sold. Information that Company publishes on the Internet may contain references or cross-references to Company products, programs, and services that are not announced or available in your country. Such references do not imply that Company intends to announce such products, programs, or services in your country. Company reserves the right to limit provision of our products and services to any person, geographic region or jurisdiction and/or to limit the quantities of any products or services we provide. Consult your local Company business contact for information regarding the products, programs and services that may be available to you. Any offer for any product or service made in the materials on this Site is void where prohibited. 

6. The Site may contain information related to medical conditions and their treatment. It is not the intention of Company to provide medical advice, diagnosis or treatment from the Site. You should not use the information contained on the Site to diagnose a health or fitness problem or disease. You should consult with your doctor, pharmacist, or other healthcare professional if you have any medical questions as only a healthcare professional can determine if a particular course of treatment is right for you. PLEASE CONSULT WITH YOUR DOCTOR, OR OTHER QUALIFIED HEALTHCARE PROFESSIONAL, BEFORE USING ANY PRODUCT DESCRIBED IN THE SITE. COMPANY IS NOT RESPONSIBLE FOR ANY INJURY OR LOSS WHICH MAY ARISE FROM RELIANCE ON INFORMATION CONTAINED ON THE SITE. 

7. Trademarks and Copyright: 

(a) The images and information contained in the Site are, to the fullest extent possible, copyrighted and otherwise proprietary. It is the policy of Company to enforce its intellectual property rights to the fullest extent of the law, including (where applicable) seeking criminal sanctions. 

(b) Company hereby authorizes you to copy materials, documents or pages published by Company on the Site for your personal, non-commercial use only, provided that (i) any copy of these documents that you make retains all copyright and other proprietary notices and any disclaimer contained herein, (ii) you make no modifications to the materials, and (iii) you do not use the materials in a manner that suggests an association with any of Company’s products or brands. Any other reproduction, retransmission, modification or use of this Site's contents requires the prior written consent of Company. Each website to which the Site links remains subject to its own copyright notice. Except as expressly provided above, nothing contained herein shall be construed as conferring any license or right under any Company copyright. 

(c) The trademarks, logos, and service marks (collectively the “Trademarks”) displayed on the Site, whether or not appearing in different type or with the trademark symbol, are registered and non-registered trademarks or service marks owned by or licensed to Company, its affiliates, subsidiaries or related companies. Nothing on this Site should be construed as granting, by implication, estoppels or otherwise, any license or right under any patent or the Trademarks. 

(d) The use or misuse of the Trademarks or any other materials, except as permitted herein, is expressly prohibited and may be in violation of copyright law, trademark law, the law of slander and libel, the law of privacy and publicity, and communications regulations and statutes. 

8. The Digital Millennium Copyright Act of 1998 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that materials hosted by Company infringe your copyright, you may send us a notice requesting that the materials be removed, or access to them blocked. If you believe in good faith that a notice of copyright infringement has been wrongly filed against you, the DMCA permits you to send us a counter-notice. Notices and counter-notices must meet statutory requirements imposed by the DMCA. One place to find more information on the DMCA is the U.S. Copyright Office website. Notices and counter-notices for the website should be sent to Otsuka America Pharmaceutical, Inc., Legal Affairs, 2440 Research Blvd, Rockville, MD 20850. 

9. Personal data available to Company through your browsing and other usage of the Site is processed only in accordance with the guidelines established in the Privacy Policy.

10. The Site may contain links to non-Company websites and third-party information. Please note that the contents of such websites and such third-party information are not controlled or influenced by Company. Any such links or information are provided merely as a convenience, and Company shall not be liable for any use thereof by visitors to the Site. In addition, a link to a non-Company website does not mean that Company endorses or accepts any responsibility for the content of such website, or the consequences of your use thereof. 

11. Company reserves the right to alter or delete the content of the Site in any way, at any time, for any reason, without prior notification, and will not be liable in any way for possible consequences of such changes. 

12. Except as otherwise expressly permitted by Company, any access or attempt to access other areas of the Company computer system or other information contained on the system for any purpose is strictly prohibited. You agree that you will not use any robot, spider, other automatic or manual process or device to “screen scrape,” monitor, or “mine,” on the Site or the content contained therein without Company’s express written permission. You will not spam any other user of the Site for any reason. You agree that you will not use any devices, software or routine to interfere or attempt to interfere with the proper working of the Site. You agree that you will not take any action that imposes an unreasonable or disproportionately large load on Company's infrastructure. You may not use framing techniques to enclose any Company trademark, logo, trade name or other proprietary information, including images, frames, content, or layout/design found on any page of the Site without Company’s express written consent. 

13. Company reserves the right to suspend or terminate your access to Company websites if you violate the Terms of Use Agreement. If your violation causes harm to others, you agree to indemnify and hold Company harmless from and against any and all loss, damage, or expense. 

14. Maryland law and controlling U.S. federal law govern any action related to these Terms of Use. No choice of law rules of any jurisdiction apply to you and Company. By using this Site you agree to submit to the personal and exclusive jurisdiction of the courts located within the State of Maryland. The failure of Company to exercise or enforce any right or provision of the Terms of Use does not constitute a waiver of such right or provision. If a court of competent jurisdiction finds any provision of the Terms of Use to be invalid, the parties nevertheless agree that the court should endeavor to give effect to the parties’ intentions as reflected in the provision, and the other provisions of the Terms of Use remain in full force and effect. These Terms of Use represent the entire understanding relating to the use of the Site and prevail over any prior or contemporaneous, conflicting, or additional communications. 

This Otsuka America Pharmaceutical, Inc. (“OAPI”) Returned Goods Policy (“Policy”) applies to product purchased either directly from OAPI or from an OAPI authorized distributor (collectively referred to herein as (“Product(s)”). OAPI reserves the right to deny credit for returns sent to third party processors other than an OAPI designated third party returns processor. OAPI will only accept the return of Product for consideration of credit, if applicable, under the conditions and limitations set out below. All products returned, whether eligible for credit or not, become the property of OAPI. This Return Goods Policy supersedes all previous policies and may be modified by OAPI at any time. 

General Terms  

All Products purchased direct and indirect must be returned directly to the OAPI designated third party returns processor to be eligible for return credit. OAPI reserves the right in its sole discretion, to refuse credit when returned through alternate channels. OAPI reserves the sole right to determine whether items qualify under this policy for return or credit. OAPI determination of the physical count of the returned Products will be final. By returning product, customer authorizes OAPI and its designee as customer’s agent to destroy, without payment or other recourse, any returned Product. All transportation charges are to be prepaid by the customer except when error is due to OAPI.

OAPI will not reimburse fees due to processing third party returns, destruction charges, shipping costs, or processing. All returns are subject to review by OAPI. Issuance of return authorization does not guarantee credit. Credit issuance is dependent upon confirmed receipt/review of return goods. Non-returnable goods received by OAPI for return will be destroyed, and credit will not be issued.

Returnable Items  

For purposes of this Policy, returns will only be accepted for credit as specified below:

• 1

  Product with shelf life no more than six (6) months prior to expiration date, or up to twelve (12) months after expiration date, which have a valid, legible NDC, lot number, expiry date, and serial number.

• 2

  Product must be in original, unaltered, and unopened container or trade package.

OAPI contracts with PharmaLink to manage the return and destruction of outdated products. To be eligible for return, all Product must be returned in accordance with the procedures set forth below to PharmaLink at the following address:

PharmaLink 
Receiving Department PLI- OAPI 
8285 Bryan Dairy Road, #160 
Largo, FL 33777

Prior Return Authorization (RA) is required for all returns. Request for Return Authorization (box RA Labels) from PharmaLink can be made as follows:

• 1 Access PharmaLink’s website at https://www.PharmaLinkinc.com and select Manufacturer RA under the Client Logins link at the top of the webpage.
  • First Time users need to create a New User login.
• 2 Select “Start a new return” and choose Otsuka America Pharmaceutical from the Manufacturer dropdown menu.
  • Create Inventory: Allows customers to enter an inventory of items in the shipment.
  • Upload Debit Memo
• 3 The following information must be supplied, or the RA Request will be declined, and product will not be eligible for return:
  • NDC Number, Product Description, Lot/Batch, Quantity, Customer’s Reference Number
  • Reason for return
  • Authorized Servicing Wholesaler
  • Debit Memo Number, Date, and Amount requested.
  • Expiration Date (In the event the package expiration date is stated in month/year format, expiration date will default to the last day of the month)
  • Returning Facility details including
    • Facility Name, Address, City, State, and Zip code
    • Facility DEA Number
    • Facility State License

• 4

  The RA must be attached to the outside of the return shipment package.

• 5

  Additional information provided to OAPI if requested

All returns must be received by the OAPI Return Agent, PharmaLink, no later than sixty (60) days after RA Label issuance with the RA Label attached on the exterior of the box together with a copy of the customer’s Debit Memo for such return(s) enclosed in the shipment.

Product returned that does not meet the criteria listed above will be quarantined, and a request will be sent back to the returning entity for any missing information. If the above information cannot be obtained by the end of the requesting business day, the product will be denied for return and sent back to the returning entity.

Should further assistance be needed in returning OAPI product to PharmaLink, contact CustomerSolutions@pharmalinkinc.com

Conditions for Credit  

• 1

  A valid Return Goods Authorization (RGA) Number must accompany all returns for proper credit. RGA Numbers are valid for 60 days from issuance. Expired RGA Numbers will be considered invalid, and no credit will be issued.

• 2

  All products must be returned to the designated OAPI returns processor, PharmaLink, within 60 days of RA to receive credit. Products that have been destroyed by customers or agents of customers will not receive credit.

• 3

  Each RGA must be in its own box. If multiple RGAs are in one box, they must be bagged separately.

• 4

  Only product from OAPI should be in the box.

• 5

  Product must be in original, unaltered, and unopened container to receive full credit value as set forth herein. For opened packages of expired product otherwise eligible for reimbursement, the reimbursement value will be based upon exact count and not to exceed the original quantity on the label. This does not apply to vials or syringes and credit will be issued for vials and/or syringes only if returned in the sealed and unopened containers.

• 6

  Product must be returned by the customer who purchased the product from OAPI. Proof of purchase may be required for credit issuance.

• 7

  It is the responsibility of the returning customer for all purchasing information.

• 8

  For ABILIFY MYCITE® (aripiprazole tablets with sensor)², ABILIFY MAINTENA® (aripiprazole) Injection³, ABILIFY ASIMTUFII® (aripiprazole)⁴, IV BUSULFEX® (busulfan) Injection⁵, JYNARQUE® (tolvaptan) Tablets⁶, REXULTI® (brexpiprazole) Tablets⁷ or SAMSCA® (tolvaptan) Tablets⁸, credit will be issued at the highest lot acquisition cost or any applicable contract price, whichever is lower.

• 9

  For ABILIFY® (aripiprazole) Tablets¹ credit for returned product will be issued at current acquisition cost (where applicable, current contract price) as of the date the returned product is received at the designated return goods processor, less ten percent (10%).

• 10

  For NUEDEXTA® (dextromethorphan/quinidine) Capsules⁹ credit for returned product will be issued at the highest lot acquisition cost less 5% or the applicable contract price, whichever is lower. Credit will be issued for full bottles only unless state law requires otherwise.

• 11

  Any credit issued by OAPI pursuant to this policy will be issued to authorized distributors of record (ADR), such as wholesalers, distributors, and other direct accounts. Indirect customers, such as retail and hospital pharmacies, will be issued credit memos through their ADR for eligible returned products. Indirect customers must also list their ADR information on the RGA.

Non-Returnable Items 

OAPI will NOT accept the following for credit:

• 1

  Product that was not purchased directly from OAPI and/or direct wholesale partners.

• 2

  Products damaged due to improper storage, handling, fire, or catastrophe.

• 3

  Products involved in salvage, bankruptcy, or insolvency proceedings.

• 4

  Private label, repackaged products, products not in the original container, non-legible lot/ expiration-dated product, or altered original product containers (e.g., bearing a pharmacy label).

• 5

  Product with shelf life more than six (6) months prior to expiration date and product past twelve (12) months of the expiry date. 

• 6

  Product acquired or purchased outside the United States and its territories. 

• 7

  Product acquired as Free Goods.

• 8

  Items returned in other than the original retail trade packages. This includes, but is not limited to, items in packages marked “professional sample,” “professional package,” “clinical trial package,” or similar special labels. 

• 9

  Overages (containers overpacked for return). 

• 10

  Opened packages of the products that are packaged as vials or syringes, unless required by law. 

• 11

  Product for which proof of purchase cannot be verified. 

• 12

  Products purchased on a non-returnable basis. 

• 13

  Items for which OAPI cannot verify original proof of purchase. 

• 14

  If product is returned without an RA, it will be rejected and returned to the customer at their expense.

Other Terms  

• 1

  OAPI reserves the right to exclude products from this policy. In the event of product exclusion from this policy, a specific returned goods policy for that product will be communicated.

• 2

  Buyer is to prepay all transportation and insurance charges. OAPI is not obligated to pay any charges incurred by the buyer in processing, shipping, or returning goods.

• 3

  OAPI reserves the right to refuse returns shipped collect.

• 4

  OAPI is not responsible for lost returns or returns damaged in shipment.

• 5

  All products are returned with the understanding that they are subject to final review and evaluation by OAPI and will be processed in accordance with the most recent returned goods policy at the time the return is received.

¹ Please see FULL PRESCRIBING INFORMATION, including BOXED WARNING, and MEDICATION GUIDE, for ABILIFY®

² Please see FULL PRESCRIBING INFORMATION, including BOXED WARNING, and MEDICATION GUIDE, for ABILIFY MYCITE®

³ Please see FULL PRESCRIBING INFORMATION, including BOXED WARNING, and MEDICATION GUIDE, for ABILIFY MAINTENA®

⁴ Please see FULL PRESCRIBING INFORMATION, including BOXED WARNING, and MEDICATION GUIDE, for ABILIFY ASIMTUFII®

⁵ Please see FULL PRESCRIBING INFORMATION, including BOXED WARNING, for IV BUSULFEX®

⁶ Please see FULL PRESCRIBING INFORMATION, including BOXED WARNING, and MEDICATION GUIDE, for JYNARQUE®

⁷ Please see FULL PRESCRIBING INFORMATION, including BOXED WARNING, and MEDICATION GUIDE, for REXULTI®

⁸ Please see FULL PRESCRIBING INFORMATION, including BOXED WARNING, and MEDICATION GUIDE, for SAMSCA®

⁹ Please see FULL PRESCRIBING INFORMATION, including BOXED WARNING, for NUEDEXTA®

The California Transparency in Supply Chains Act requires large retailers and manufacturers conducting business in California to provide information to consumers regarding their efforts to eradicate slavery and human trafficking from their direct supply chains. 

Otsuka promotes ethical labor practices and the highest standards of business conduct both internally and within our direct supply chain.  Otsuka’s parent company, Otsuka Holdings, Ltd, is a signatory to the United Nations Global Compact, a voluntary initiative that unites companies in their commitment to create a sustainable and inclusive global economy.  By signing this compact, Otsuka has pledged to advance numerous human rights principles, including the elimination of all forms of forced and compulsory labor and the effective abolition of child labor.  These principles are consistent with Otsuka’s long-standing values and the expectations stipulated in our Code of Ethics and Professional Conduct, on which relevant Otsuka suppliers are trained and certified. 

Furthermore, all manufacturing of Otsuka pharmaceuticals approved for distribution in the United States complies with United States Food and Drug Administration (FDA) Current Good Manufacturing Practice (cGMP) regulations governing the methods, facilities, controls, and personnel qualifications necessary for the manufacturing, processing, and packing of a drug product.  These regulations not only set high quality thresholds for the work environment, but also impose stringent training requirements for the individuals working in these facilities. 

Verification 

All Otsuka employees are required to complete training and certify annually to our Code of Ethics and Professional Conduct.  The Code follows the principles set forth in the United Nations Declaration of Human Rights and prohibits any employment by Otsuka of underage children or forced labor, as well as any form of physical punishment or abuse.  Otsuka also maintains a Code for suppliers, which stipulates that all third parties with whom Otsuka does business are expected to provide a workplace free of human rights abuses, provide wages and benefits that comply with national laws and industry standards, and comply with all applicable labor and employment laws—including those that prohibit human trafficking and the employment of forced, bonded, enslaved, indentured, or involuntary prison labor.  Relevant suppliers must also train and certify annually to the Code. 

Additionally, the sourcing, manufacturing, and packaging of Otsuka pharmaceutical products for distribution in the United States is governed by FDA cGMP regulations, which include specific personnel and workplace qualifications.  Otsuka verifies manufacturing suppliers’ compliance with FDA cGMP regulations through regular audits and site inspections. 

Supplier Audits  

Otsuka conducts due diligence on all suppliers prior to their engagement, as well as throughout the period of their engagement.  This includes initial screening and audits if appropriate, as well as regular audits and site inspections of manufacturing and packaging suppliers to ensure compliance with our quality agreements.  Otsuka suppliers are also subject to ad hoc audits and inspection by government agencies, including FDA. 

While slavery and human trafficking are not specific targets of these audits, Otsuka personnel would be required to escalate any such observations or suspicions immediately. 

Supplier Certification 

All contractual arrangements between Otsuka and our suppliers stipulate compliance with local laws, rules, and regulations, which would include those concerning labor and employment in the region where the supplier operates. 

Where Otsuka third parties are also required to complete training on our Code of Ethics and Professional Conduct for suppliers based on their role and the services they provide, they must certify to their understanding and adherence.  Otsuka Ethics & Compliance monitors adherence to this requirement and third parties who fail to comply may be disengaged. 

Internal Accountability 

Otsuka requires all employees and suppliers to report, via our third party Integrity Line or directly to Otsuka Ethics & Compliance, any actual or suspected violations of the Code or any applicable law or policy in connection with the work done for us.  Reports to the Integrity Line can be made anonymously. 

Violations are escalated to a cross-functional investigations committee and handled through appropriate corrective and preventive actions such as procedural modifications, training, disciplinary measures or contract termination, and/or self-reporting if required by law.  

The following workplace standards apply: 

Code of Ethics and Professional Conduct for employees
Code of Ethics and Professional Conduct for suppliers

Training 

Otsuka employees at every level, relevant Otsuka suppliers, and our Board of Directors are required annually to review our Code of Ethics and Professional Conduct and certify to their understanding and adherence.  The Code outlines specific expectations and prohibitions concerning labor and human rights, including slavery and human trafficking. 

Otsuka Ethics & Compliance monitors adherence to this annual training and certification requirement, and noncompliance may result in disciplinary action or termination.  Our supplier contracts may also stipulate compliance training requirements or alternative training assurances, including audit rights.